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We investigated tile effect of dopamine on the m wvo expression fbrain-derived ncurotrophic factor (BDNF) ill tile ~tnatum ofmouse. BDNF 
mRNA ~xpre~sion n the ~triatum, which wa~quantified with the rever~e tranbcnpta~e polymerase chain reaction, was up-regulated from 2 h after 
oraladrnmistrationoflevodopa, a precursorofdopamme. Theincreasewa~ustain~.~d for 16hCo.admm~strationofhalope~idotpartmllymh:bited 
dopamiae-mduced BDNF enhancement. The~e data ~ug~cst that dop,tminergic stimulatton diiectly promotes the xptension f BDNF in the 
striatttm inwvo, 
Brain-derived neurotrophic factor; Dopamme; Tr,mscnption, Stnatuln 
1. INTRODUCTION 
Brain-derived neurotrophie factor (BDNF) is puri- 
fied as a protein with a property to support embryonic 
neurons [1,2]. Nerve growth factor (NGF) [3], neurotro- 
phin 3 (NT3) [4--9], neurotrophin 4 (NT4) [10], and 
neurotrophin 5 (NTS) [11] have similar biological activ- 
ities and homologous protein structures to BDNF, 
composing a gene family, The spectra of target neurons 
of these neurotrophic thctors are distinct but partially 
overlap. For example, both BDNF and NGF have a 
trophic effect for dorsal root ganglion neurons and 
cholinergic neurons from basal forebrain nuclei [12]. 
However, retina ganglion cells [13] respond for BDNF 
but not for NGF. BDNF supports placode and neural- 
crest-derived sensory neurons which are not responsive 
to NGF [ 13-15]. The selective responsiveness i  presum- 
ably derived from dift~erent expression pnttern~ of neu- 
rotrophic receptors. 
We are interested in developing therapies for Parkin- 
son's disease (PD) which is caused mainly by neural 
degeneration in the substantia nigra located in the 
midbrain. The nigral neurotransmitter, dopamine, is re- 
duced in PD, causing hypoaetivity of neurons in the 
striatum which receives axonal projection from the sub- 
stantia nigra. Ordinarily PD patients are treated with 
dopamine supplements. However supplementary ther- 
apy is not aimed directly at prevention of nigral degen- 
eration. A candidate substance which could delay the 
nigral degeneration if BDNF, since BDNF,  but not 
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NGF,  extends the survival of  primary cultured central 
dopaminergic neurons [16,17]. Therefore, modulating 
the expression of  BDNF in brains of PD patients would 
be a different ype of therapy fiom the replacement of 
neurotransrnltter of nigral neurons. In this sense, it is 
important to survey the agents which may influence the 
expression of BDNF.  It is noteworthy that BDNF ex- 
pression is up-regulated by potassium-induced depolar- 
ization in hippocampal neurons [18]. In addition, the 
application of  kainic acid 118-20] and experimental epi- 
lepsy [21] seem to promote BDNF expression in the 
hippocampus through depolarization. It is possible that 
dopamine induces depolarization on the striatal neu- 
rons when released from the terminal of the nigro-stria- 
tal fibers and, conversely, neurotrophic factors released 
from the striatum wotdd support the survival of ~igral 
neurons through the retrograde transport. Therefore, 
we investigated the effects of dopamine on the expres- 
sion of  BDNF in the striatum. 
2. MATERIALS  AND METHODS 
2.1. RNA pt ¢paratl~n and RT-PCR 
Balb/e m~ce were dissect~xl at each interval after tile administration 
of a combined drug of levodopa O-hydroxy-t.-tyrosme)/carbadopa (S- 
¢t-hydrazino-3,4-dihydroxy-~Mnethylbenzenepropanoic acid mo hy- 
drate) 10' 1 orally as a fine sttspensJon. Ordinarily 0 2 mg of levodopa/g 
body weight of mouse was administered. For the mlubition eapen- 
meat, 1 /~ of haloperidol/fi body weight of mouse was eo-admlnis. 
tered. The mice were observed for at least 1 h after administration to 
confirm that they d~d not vomit. Bram~ were coronally s~tioned 
a~ordln8 to an anatomxeal all,t~ Rel~ions of inter~t ware separated 
out, rapidly frozen m liquid mtrogen, and kept at -80°C untd use. 
a~,.u...,~ to the. i'rl.t.~d O~ 
Chomzin~ki and Sacchi [22]. Briefly, 5-10 m~ of brain tmsue was 
homogenated m 800 #1 ol'solatloa D (4M gu,undmmm thioeyanate, 
i 38 Oubhshed b), £1~evter Sctence Pubh~hers B.I/ 
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25 mM sodium citrate, 0.5% N-lauroylsako~yl, 0.1 M 2-mgreaptoetha- 
nol). After a brief ¢¢ntrifugation, 100/el of :2 M sodium acetate (pH 
4.0) wan added to the supematant and m~xed by inversion, 800/.tl of 
phenol saturated with water was added and mixed, and then 200/zl 
of chloroform-isoamylalcolaol (49:1) was added and vortexed vigor. 
ously for I ram. The aqueous phase was recovered after a centrifuge- 
iron, added wtth 800 ,¢tl of -20°C i~opropanol. The ~olution was 
dtvidgd to three Eppendorf tubes, centrifuged for 30 min at 15,000 rpm 
at 4°C. The pellet was washed wtth 70% ethanol and dried One of the 
tubes was used for cntimation of RNA amounts. Since expression of 
I~DNF in the ntriatum is very low under physiological conditiom 
[23,24], we used reverse transcnptase polymerase chain reacuon tRT- 
PCR) for the estimation. RT-PCR was performed according to the 
method escribed by Zal'ra et el. [18]. 200 ng of total RNA, 0.1/aDd 
of both d~reet~onal primers, 1 x RT-PCR bulfer (10 mM Tl~s-HCi, pH 
8.3, 50 mM KCI, 1.5 mM MgCI.,, 0.1 me:/ml gelatin, 0.1% Triton 
X.100, 0.:25 mM dNTPs, 5 U RNase inhibitor (Bochrmger- 
Mannhe~m, Germany), 3 2 U AMV-revers¢ transenpta~e XL (Life 
Science Inc., USA), and 2 U Taq polymerase (Pcrkin-Elmer Cetus 
Instruments, USA) were m~xed in a total volume of25.ul. PCR primer~ 
for neurofiloanents were added to th~s reaction solution when neces- 
saw. The -~olatioa wan incubated at 41°C for 30 nun and denatured 
at 94°C for 3 rain and used for PCR. Bas~cally, the thermal cycle 
condition was a~ follow,ng 94°C for I rain, 55~C for 1 rain, and 72°C 
for 1 lain. 
s*a  f, aa~¢ a a f~a 1~ za  • ~ *a i t i t  m 
HGF S STI~ VFIIMG~ ~'SVC~SVSV~V- -GO I~TTATD l KGKEV~VLAEV/I I MI~SVF - 
NT-3 ~/~HI~nRGEYSVCDSESLW/T- -D I~SAID IRGaQVTV~IKTGNb~V-  
~T-4 /~SG S D ~VS LS RI~G~ LSVCDSVI~ VI~T- -DKRTAVDDR~I~ I%~MSE IT~qLTGP~ 
~T-5 GVSETA~ ~SRRG E L/WCD/~VSGNVT- -D I~RTAVDLRGREVEV~AAC~ -~p L 
l~Dt~P HSD PARRGE LSVCD S i SEWVTA/~ I~TAVDM~ G~EI~/PVSKC.QL-  
V1 p~Imer ~DNF pzo l~ 
NGF RQYFFETRCP~ ....... S ~4 PVESGCRG Z DS I~WNS¥CTTTIIT~I~%LT'/D EKQ 
NT-3 K~YFYETRCRE ...... .  ~ VKNGCRG I DD FdlWNS Q~KT~TSEMNR 
~T-4 KQY£FETRCNP ...... .  S GSTTRGCR~VDI~Q~ S ECKAKQSYVI~I~T~I)AI~ 
N¢-5 RQY~FET RCFdKDI~/~E~GGP GAGGGGGRGVDRR~NVS EC~QS~VRALTR~ 
I~D~ ~QY~YZTRCNP ...... .  MGYTI~GCRG Z g I~q~qSQCI~TTQRIq/I~TI~SI~ 
~14 pEtE  
tan  aa f taa  ta t  
I~GF -/~.k'R g I R I O AC VC V .~ S RlCd~T~:~ G 
NT-3 LVGk'RW Z R Z DTS CVC/LT.,SP~ T GRT 
N?-4 LVGhTI~H I R T D'r,~c VCTLLS P, TGR? 
NT-5 ?,VG~#RW Z R I DT/~CVCTLLS RTGR/~ 
I~DN~" RTGNR/ZI~ ZDTSCVCTLT I I~RG~ 
FIg. 1. Posalons of the primers used in RT-PCR and the oligonud¢o- 
tide probe a.~gd m Southern blotting are indicated with arrows and a 
double underline below the sequence comparison of live members of 
neurotrophins Amino acid sequences conserved b tween more than 
four members arc indicated with asterisks. The pnmer~ and the probe 
correspond to the specific sequence of BDNF. 
A B 
291 bp l~  
1 2 3 4 5 6 7  8 1 2 3 4 5 6 7  8 
"~:, qg/a 
C 
1 2 3 4 5 6 7 8 9 1 0  11 
Fig. 2, The BDNF transcript can be detected with RT-PCR in the striatum. (A) 20 rounds of thermal cycles amplified eDNA bands from 1/~g 
of the hippocampal total RNA independently prepared (lanes 2,3), but not amplified from 1/a 8 of total RNA prepared from the striatum (lanes 
4,5) and a ventral half of the midbrain (lanes 6,7). (B) Thin al~arose gel was blotted to a nylon membrane and hybridized w~th a l~DHF-spec~fic 
o!igonuc!eotlde probe. The probe hybridized w~th the amplified bands, ind~c:ttmg that our RT-PCR could detect 1he BDNF transcript (C) BDNF 
cDNA~ were amphfied from total RNA of the hlppocampas (lane.~ 2--4), striatum (lanes 5-7), and a ventral iaalf of the mldomin Iianen 8-10) Th~ 
number of rounds of thermal cycle are as follows: lane 2, 20; lane 3, 30; lane 4, 40; lane 5, 30; lane 6, 40; lane 7, 50; lane 8, 30, lane 9, 40; 
lane 10, 50. RT-PCR amphfication reached a plateau between 30 and 40 rounds when using striatal RNA. 
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Fig. 3 Time-course of BDNF up-resalation after oral administration f 0 2 m~8 body weiglat ofmouse of levodopa. (A) Brain tissues were dissected 
without administration (lane 2) or at 2 h (lane 3), 4 h (hme 4), 8 h (lane 5), 16 h (lane 6), and 24 h (lane 7) after admmlstrauon of levodopa. Lane 
1 shows molecular weight markers, £DNA digested by Hmdlll. 1 ~tg of total RNA from the bmatum wau tt~cd in RT-PCR. Amplified cDNAs 
were separated with a 3% Nusivc/asaro~c gel eDNA bands of BDNF (291 bp) and nctu ofilanaent-M (216 bp) are indicated with arrowheads (BDNF 
and NF). tB) Amount~ of BDNF cDNAs are ~tandardlzed with those of neurofilament Values l~prebent the mean + S.D. of 4 determinations 
and are c~presscd a5 p,-rccntages of  the internal standard. 
2 2 So,them blotting 
After removal of mineral oil, the PCR product was extracted txwce 
with chloroform, ethanol precipitated, washed with 70% ethanol, 
dried by lyophilizer, and suspended in 15~1 of TE buffer PCR prod- 
ucts were separated on a 3% Nttswe/agarose 3 I ~el. Southern blotting 
wa~ done basically according to the method described previously [25]. 
The ohsonucleotlde probe was radmlabelled with T4 polynucleot~de 
kina~e (Takara, Japan). Prehybndlzatlon was done in 5 × SSC, 50% 
deionized formamid¢, 1% SDS, and 200 ng/ml of ~onicated ~almon 
sperm DNA at 42°C for 6 h. Hybridization was done m the same 
solution by adding about 2 ng/ml radlolabelled ohgonucleotide probe 
at 42°C for 24 h. Filte,'-~ were washed twice in 5 × SSC, 0.1% SDS, at 
40°C for 20 mm and sequentially in 0 2 × SSC, 0.1% SDS, at 55°C for 
30 mm. Fdter~ were exposed to Kodak XOMAT film5 overnight at 
-800C 
2.3. Quantification of PCR product 
Since the blotting efficiency was sometimes variable, we e~timated 
the amounts of PCR productb directly from Polaroid films ofagarose 
Coin ~tained with etludium bromide. Polaroid films were read wLth 
,mace analyzer (Ep~on GTSO09) Signal areas and mean mtenslties 
were analyzed with Color magician 111. Signals were standm diced with 
ncurofilamcnt PCR product. 
2.4. Pruners for PCR and probes for Southern blotting 
PCR primers for the amplification of BDNF were CACTCGGA- 
CCCCGCCCGCCG (VI primer) and TCGTTTTTTGCTATC- 
CATGG (V4 primer). The oligonucleotide probe used m Southern 
blottin8 was CTCGAAAAAGTCCCCGTCTCGAAAGGCCAAC- 
TGAAGCAG PCR primers for neurofilament-M were GAAACT- 
CAGGAGAAGGGCAGT and CTCATGCTCTTCAACCTT'I"I'G. 
The neurofilament expected product i~ 216 bp in length. 
3. RESULTS AND DISCUSSION 
In order to develop the specificity of RT-PCRo we 
made an oligonucleotide probe corresponding to a spe- 
cific sequence of BDNF in its variable region between 
PCR primers (Fig. 1) and Southern blotted the PCR 
products. This probe hybridized to the bands of ex- 
pected DNA length, indicating that these bands were 
amplified specifically from the BDNF mRNA (Fig. 
2A,B). BDNF expression i  the striatttm has previously 
been quantified with Northern blotting by other groups, 
showing the transcript level is extremely low or almost 
undetectable [23,24]. In our experiments, with 20 
rounds of thermal cycle amplification, eDNA was am- 
plified from hippocampal total RNA but not obviously 
from total RNA of the striatum and the ventral half of 
the midbrain, including the substantia nigra (Fig. 2A). 
However, using 30-50 rounds of thermal cycle amplifi- 
cation, we could clearly detect eDNA bands fiom stria- 
tal total RNA (Fig. 2C). Thi~ finding is compatible with 
the estimation by l~rorthern blotting in the previous re- 
ports [23,24]. 
Using 23 rounds of thermal cycles, which is within the 
linear amplification range, we investigated the time- 
course of BDNF expression after oral administration f
levodopa (Fig. 3A,B). We used 0.2 mg of levodopa/g 
body weight of mouse in this experiment. As an internal 
standard for each RT-PCR reaction, we mixed PCR 
primers tbr neurofilament-M, which were selected as a 
neuronal marker, in order to adjust the number of neu- 
rons. BDNF expression is rapidly up-regulated from 2 
h after oral administration of levodopa. The amount of 
transcript did not seem to change obviously at 1 h after 
administration (data not shown). Considering the n c- 
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FAg. 4. Up-regulation or BDNF tlan~enption by levodopa is do~e dependent and pattiall~, inhibited by co-administration of halopendol (A) 
Amount~ of adrnmmtration (mg/g body weight of mouse) of lcvodopa welt 0 01 (lane 2), 0 1 (lane 3), and 0 2 (lane 4) 1 
,(tglg body weight o1" mouse of halopcridol was co,admmtstr,ated ,a, lth 0 2 mg/g body weight of mouse of levodopa (lane 5). Brain ti~sucb were 
dinsected at 6 h aflcr administrations RT-PCR was done a~ described bclblc eDNA were ~cparatcd m a 3% Nu~ive/.'tgarose gel Lane 1 ~hows 
molecular weight markers. (B) Fold mclease of BDNF tran.scnpt. Amount~ of BDNF eDNA were standardized with tho~e ofneurofilarnent-M. 
The value~ ate means i S.D, (n = 4). (C) Inhibaton of BDNF expression by halopelidol BDNF cxpre.~slon wits quantified after levodopa (0.2 
mg/g body weight) administration alone or co- administration oflevodopa nd halopendol ( 1 tag,/g body weight). BDNF expreb~lon was standard- 
ized w~th the nemofilament control. The values prcncnt are mcan~ + S D The value of co-adnumstrat~on ~s exploited as a relative per~ntage to 
the mean of levodopa drmmstratton, x~,h|ch is set dS 100%. 
cssary time for absorption of levodopa from the gut, 
up-regulation begins within 2 h of exposure of neurons 
to dopamme. The response is equally rapid as that in- 
duced by kainie acid in hippoeampal neurons [18]. The 
enhancement of BDNF expression lasted for 16 h after 
oral administration f levodopa. This period is also 
compatible w~th that caused by kainic acid stimula) ion 
[18]. The similarity of the time-courses suggests that 
depolarization by transmitters would induce ~imilar cel- 
lular responses which regulate BDNF transcription. In 
order to comprehend this regulating mechanistn of 
BDNF expression, transcriptional control regions of 
the chromosome must be analyzed. A part of the BDNF 
gene, 2.2 kbp of 5' flanking region, has been analyzed 
by chlGrarnphenicol acetyltransferase (CAT) assay 
using a gliorna cell line [27]. However, there are no 
sequences matching tile consensus equences of pubA 
lished enhancer elements within this 2.2 kbp. Therefore 
transcription factors which act on this portion of the 
genc ,~.,,"-'~ dcfinc ""~,,,,. -I .... ..,i of BDNF expression are not 
yet known. Furthermore there remains the possibility 
that some other regions of the chromosome influence 
141 
Volume 313, number 2 FEBS LETTERS November 1992 
the transcription of BDNF. The up-regulation of 
BDNF by transmitters might be caused by de hove 
synthesis of known and/or unknown transcription fac- 
tors are depolarization, or by modification of some 
transcription factors, uch as an activation of  jun by 
dephosphoryl.'ttion [28]. These questions hould be ana- 
lyzed in the future. 
As the next step~ we grossly evaluated the dose-re- 
sponse in order to see whether a clinical application is 
possible. Administration of 0.01 mg of levodopa/g body 
weight of mouse is inadequate to elicit up-regulation of 
BDNF (Fig. 4A,B), suggesting ordinary doses of le- 
vodcpa used for PD patients are far less than the neces- 
sary amount. Co-administration of haloperidol, a 
dopaminergtc antagonist, partially blocked the en- 
hancement of BDNF expression by dopamine (Fig. 4C). 
The prompt increase of BDNF expression and its inhi- 
bition by an antagonist suggest the possibility that 
dopamine directly promotes BDNF expression. 
It is still an open question how neurons are kept alive 
in physiological and pathological conditions. Neurotro- 
phic factors are clearly candidates for these life-promot- 
ing agents. Neurotrophins at least participate in the 
programmed cell death during development, since ap- 
plication of NGF increases the number of surviving 
neurons in vivo [30]. Ciliary neurotrophic factor 
(CNTF), another type of  trophic factor, supports the 
survival of injured or congemtally abnormal motor neu- 
rons in vivo [3132]. BDNF elongates the survival of 
nigral neurons in primary culture [16,17]. Neurons re- 
ceive these neurotrophie factors from their target cells, 
including neurons themselves. Trophic factors are taken 
up from the axonal terminal and transported retro- 
gradely to the cell body and induce trophic effects (for 
review see [29]). On the other hand, recent reports re- 
vealed tlaat neural activation itself elicits early the gene 
response of neurotrophie tatters [18-20]. These two ob- 
servations suggest a hypothetical relationship between 
neurons and their target neurons; target neurons seem 
to produce neurotrophic factors more abundantly and 
release them to neurons which send axons to the target 
nettrons, when the neural circuit which connects the two 
groups of neurons is activated. Our results in the nigro- 
striatal pathway seem to support this hypothesis. It is 
possible to specuhtte that doparninergic stimulation 
supports nigral neurons through the up-regulation of 
BDNF expression in the striatum. However, we do not 
know to what extent BDNF actually participates in the 
survival of nigral neurons in a physiological or a pa- 
thological condition. Tiffs question should be clarified 
in the future in order to develop the application of 
BDNF for the therapy of neural degeneration. 
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